Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Silexion Therapeutics (NASDAQ: SLXN) received Israeli Ministry of Health approval on March 24, 2026 to initiate a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, marking advancement to clinical-stage development.SIL204 targets a broad range of KRAS mutations (present in >90% of pancreatic cancers), follows strong preclinical anti-tumor activity, completed toxicology studies, and plans a Germany filing by quarter-end with EU filings planned in early 2027.

#SLXN Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Silexion Therapeutics (NASDAQ: SLXN) reported Q4 and full-year 2025 results and business progress for SIL204.Key points: expanded preclinical activity across eight KRAS mutations and four cancer types; completed two-species GLP toxicology; submitted Phase 2/3 trial application in Israel; cash $6.0M; raised ~$18.6M in 2025.

#SLXN Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting Silexion Therapeutics (NASDAQ:SLXN) reminds shareholders of an Extraordinary General Meeting on March 16, 2026 to vote on two capital actions: increasing authorized share capital from US$121,500 (9,000,000 shares) to US$796,500 (59,000,000 shares), and amending its 2024 Equity Incentive Plan evergreen to yield a 10% fully diluted reserve. The Board unanimously recommends voting FOR all proposals to support clinical development of SIL-204, potential Nasdaq compliance measures, and employee incentive capacity. Shareholders are urged to vote promptly; proxy assistance is available via Laurel Hill Advisory Group.

#SLXN Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026 Silexion Therapeutics (NASDAQ: SLXN) reported 2025 preclinical and operational progress for its lead RNAi asset SIL204, including >90% tumor inhibition in multiple human KRAS-mutant models and validated activity against 8 KRAS mutations. The company completed two‑species toxicology with no systemic organ toxicity reported, received positive written scientific advice from Germany’s BfArM, raised >$18 million, regained Nasdaq compliance, and established manufacturing and CRO partnerships. Silexion plans a Phase 2/3 LAPC trial with regulatory submissions and clinical start targeted in H1 2026 (Q1 regulatory responses expected).

#SLXN Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer Silexion Therapeutics (NASDAQ:SLXN) submitted a Phase 2/3 clinical trial application in Israel for SIL204 in locally advanced pancreatic cancer, targeting a trial start in Q2 2026. The filing follows positive Scientific Advice from the German regulator (BfArM), two species toxicology studies showing no systemic organ toxicity, and preclinical data reporting up to 99.7% cancer cell inhibition across multiple KRAS mutations. Silexion plans additional regulatory submissions in Germany and the EU in Q1 2026, with U.S. site expansion expected after completion of the safety run-in. The Israeli portion is being prepared in collaboration with Sheba Medical Center, subject to approvals.

#SLXN Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer Silexion Therapeutics (NASDAQ: SLXN) received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices (BfArM) on the proposed design of its planned Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer.The feedback confirmed acceptability of core elements—clinical design, dosing, patient population, nonclinical support, and CMC/manufacturing—and will be incorporated into regulatory submissions in Israel by end-Q4 2025 and in Germany in Q1 2026. The company remains on track to initiate the Phase 2/3 trial in H1 2026, pending regulatory clearance.

#SLXN Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Advances SIL204 Toward Phase 2/3 After Completing Toxicology Studies Silexion Therapeutics (NASDAQ: SLXN) announced that it has successfully completed the required two-species toxicology studies for SIL204, its next-generation RN

(NASDAQ: #SLXN)
#SLXNTheraputics completed toxicology studies for SIL204, confirming no systemic organ toxicity and enabling progression toward Phase 2/3 trials in advanced pancreatic cancer set for Q2 2026.
prismmarketview.com/silexion-adv...

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer Silexion Therapeutics (NASDAQ: SLXN) completed two‑species toxicology studies for SIL204, its next‑generation siRNA therapy targeting mutated KRAS, which showed no systemic organ toxicity. The company said these results support planned regulatory submissions to Israel and Germany and keep Silexion on track to start a Phase 2/3 trial in locally advanced pancreatic cancer in Q2 2026. Preclinical data cited include broad in vitro KRAS mutant cell‑line growth inhibition and systemic anti‑tumor activity in pancreatic sites. Management noted a secured CRO partner and an integrated intratumoral plus systemic dosing approach as next steps toward clinical development.

#SLXN Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

www.stocktitan.net/news/SLXN/silexion-thera...

#SLXN Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SLXN/silexion-thera...

📢 Stocks Trending NOW: #OPEN #WLDS #KLAR #BMNR #TTD #VNCE #ADBE #SLXN #UPS #AIRE

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNA interference therapies for KRAS-driven cancers, has announced the pricing of a $6.0 million public offering. The offering includes 1,500,000 ordinary shares (or equivalents) with accompanying series A and B warrants at $4.00 per share.The offering includes series A warrants with a 5-year term and series B warrants with a 12-month term, both with a $4.00 exercise price. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will support pre-clinical studies and general corporate purposes, with closing expected around September 12, 2025.

#SLXN Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

www.stocktitan.net/news/SLXN/silexion-thera...

Breakthrough: Cancer Drug Reaches All Major Metastatic Sites - Silexion's SIL204 Shows Promise for Fatal Disease Silexion's SIL204 demonstrates distribution to liver, lung, and peritoneum with significant tumor reduction (p<0.01). Phase 2/3 trials planned for H1 2026 targeting KRAS-driven cancers.

#SLXN Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 Silexion Therapeutics (NASDAQ:SLXN) has selected AMS Advanced Medical Services GmbH as its Contract Research Organization (CRO) to support upcoming Phase 2/3 clinical trials for SIL204, their RNA interference therapy targeting KRAS-driven cancers.The partnership follows impressive preclinical results showing up to 97% inhibition in pancreatic cancer cells, ~90% inhibition in colorectal cancer cells, and significant activity in lung cancer cell lines. SIL204 has demonstrated effectiveness against multiple KRAS mutations including G12D, G12V, G12R, Q61H, and G13D.Regulatory submissions are planned for Q4 2025 (Israel) and Q1 2026 (EU), with Phase 2/3 trials expected to commence in H1 2026. The trials will evaluate SIL204's dual-route administration approach in locally advanced pancreatic cancer patients.

#SLXN Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Silexion Therapeutics Corp.

#SLXN Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company focused on RNAi therapies for KRAS-driven cancers, has announced warrant exercise agreements totaling $1.8 million in gross proceeds. The agreement involves the immediate exercise of 152,106 outstanding warrants at $11.57 per share.As part of the transaction, the company will issue new unregistered warrants to purchase up to 304,212 ordinary shares at an exercise price of $11.32 per share. These new warrants will have a 24-month term and will become exercisable following shareholder approval of increased authorized shares. H.C. Wainwright & Co. serves as the exclusive placement agent for this offering.

#SLXN Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

www.stocktitan.net/news/SLXN/silexion-thera...

NASDAQ: #SLXN
Silexion Therapeutics announces promising preclinical results for its novel cancer therapy, showing strong anti-tumor activity in early studies. A big step forward in advancing next-gen oncology treatments.
#SLXNTheraputics
prismmarketview.com/silexion-the...

Silexion Therapeutics Announces 1-for-15 Reverse Share Split Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has announced a 1-for-15 reverse share split effective after market close on July 28, 2025. Trading on a split-adjusted basis will begin on July 29, 2025.The reverse split will automatically combine every fifteen ordinary shares into one share, with the par value increasing from $0.0009 to $0.0135 per share. The move aims to maintain Nasdaq listing compliance and follows recent preclinical breakthroughs with SIL-204. Shareholders holding shares in book-entry form or through brokers will have their shares automatically adjusted.

#SLXN Silexion Therapeutics Announces 1-for-15 Reverse Share Split

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines Silexion Therapeutics (NASDAQ: SLXN) has announced positive preclinical results for its SIL204 drug candidate in human lung cancer cell lines. The study demonstrated significant dose-dependent inhibition in lung cancer cells with KRAS G12D mutations, validating the company's lipid-conjugated delivery system.The company is preparing for a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for KRAS-driven solid tumor cancers, utilizing both intratumoral and systemic delivery approaches. Silexion is also conducting additional studies on a previously untested KRAS mutation to potentially establish SIL204 as a pan-KRAS treatment.The target market is substantial, with KRAS mutations present in 90% of pancreatic cancers, 45% of colorectal cancers, and 30% of lung cancers, representing a combined global treatment market exceeding $30 billion annually.

#SLXN Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers Silexion Therapeutics (NASDAQ: SLXN) has announced breakthrough preclinical results for its RNAi therapeutic candidate SIL204, showing significant efficacy against pancreatic, colorectal, and lung (NSCLC) cancer cell lines. The drug demonstrated powerful anti-tumor activity in cells with KRAS G12D mutations, achieving an impressive ~90% inhibition rate in GP2D colorectal cancer cells. SIL204's lipid-conjugated delivery system enabled potent activity at nanomolar concentrations across multiple cancer types. The therapy targets KRAS mutations, which occur in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-squamous non-small-cell lung cancers. These indications represent a combined global treatment market exceeding $30 billion annually.

#SLXN Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer Silexion Therapeutics (NASDAQ: SLXN) has completed a crucial preclinical study evaluating its RNAi therapeutic candidate SIL204 across multiple cancer types. The study assessed SIL204's potential in treating colorectal cancer (GP2D), lung cancer (A427), and pancreatic cancer (Panc-1) cell lines with KRAS mutations.The company plans to announce comprehensive results in the coming days. This expansion beyond pancreatic cancer targets a significant market opportunity, as KRAS mutations occur in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-small-cell lung cancers. The combined treatment market for these indications exceeds $30 billion annually.

#SLXN Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Silexion Therapeutics (NASDAQ: SLXN) reported Q1 2025 financial results and business updates, highlighting significant progress in their RNAi therapy development for KRAS-driven cancers. Their lead candidate SIL204 demonstrated remarkable efficacy in preclinical studies, showing ~70-80% reduction in tumor cells and decreased metastatic spread in orthotopic models. The company strengthened its financial position by raising over $9 million in gross funds during Q1. Cash position improved to $6.2 million as of March 31, 2025, up from $1.2 million at end-2024. Q1 operating expenses were $1.7 million, with net loss at $1.7 million. The company announced a strategic collaboration with Catalent for SIL204's formulation development and unveiled plans for clinical trials in H1 2026.

#SLXN Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SLXN/silexion-thera...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Apr 23rd - #RXRX #SOUN #JBLU #RIG #WULF #SNOA #AREB #ZIM #BB #TGB #CLSK #STNE #SMR #SLXN #QS #QBTS #CEP #BTCS #BORR #ASM - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent Next-gen siRNA therapy shows promising results against pancreatic cancer. Strategic partnership accelerates development of multi-KRAS targeting drug. See trial timeline.

#SLXN Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data Silexion Therapeutics (NASDAQ: SLXN) has announced an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven pancreatic cancer. The new strategy combines both intratumoral and systemic administration approaches to target primary tumors and metastases.The expansion follows promising preclinical data showing significant tumor growth inhibition in orthotopic models through systemic administration. Recent studies demonstrated SIL204's ability to reduce metastases to secondary organs, with pharmacokinetic data showing sustained drug levels for approximately two months after a single subcutaneous dose.The development roadmap includes:Additional toxicology and pharmacodynamic studies throughout 2025Planned regulatory submissions to Israel Ministry of Health in H2 2025European Union submission targeted for H1 2026Human trials initiation planned for H1 2026

#SLXN Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

www.stocktitan.net/news/SLXN/silexion-thera...

Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 Silexion's enhanced strategy for SIL204 targets KRAS-driven pancreatic cancer using innovative RNAi therapy. Comprehensive plan reveals multiple delivery approaches.

#SLXN Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

www.stocktitan.net/news/SLXN/silexion-thera...

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Silexion Therapeutics (NASDAQ: SLXN) reported its financial results for 2024, marking a transformative year highlighted by its Nasdaq listing and advancement in RNAi therapies for KRAS-driven cancers. The company's second-generation candidate SIL204 showed promising results in reducing tumor burden and metastatic spread in pancreatic cancer models.Key financial highlights include:Cash position of $1.2M as of December 31, 2024 (down from $4.6M in 2023)Total operating expenses increased to $12.6M (from $4.7M in 2023)Net loss of $16.5M (compared to $5.1M in 2023)Recent funding raised approximately $9.1M gross proceeds ($7.9M net)Clinical highlights include a 56% objective response rate in Phase 2 LODER™ trial for pancreatic cancer patients with KRAS mutations, and plans to initiate SIL204 Phase 2/3 trials by first half of 2026.

#SLXN Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/SLXN/silexion-thera...

Just In: ( NASDAQ: #SLXN ) Silexion Therapeutics Shares Positive Initial Data from SIL204's Orthotopic Pancreatic Cancer Models